fulvestrant has been researched along with Soft Tissue Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aktas, B; Barry, WT; Carey, LA; Carrasco, E; Casas, M; Cirrincione, CT; De la Haba-Rodríguez, J; Dickler, MN; Furlanetto, J; Garcia-Saenz, JA; Guerrero-Zotano, A; Hahn, O; Hudis, C; Hyslop, T; Loibl, S; Martín, M; Martinez-Jañez, N; Mehta, K; Morales, S; Partridge, A; Rodriguez-Martin, C; Winer, E | 1 |
1 trial(s) available for fulvestrant and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Evaluation Studies as Topic; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Soft Tissue Neoplasms; Survival Rate; Tamoxifen | 2019 |